Exploring the N-Glycosylation Profile of Glycoprotein B from Human Cytomegalovirus Expressed in CHO and Nicotiana tabacum BY-2 Cells

International Journal of Molecular Sciences
Nicolas SmargiassoCatherine Navarre

Abstract

The ability to control the glycosylation pattern of recombinant viral glycoproteins represents a major prerequisite before their use as vaccines. The aim of this study consisted of expressing the large soluble ectodomain of glycoprotein B (gB) from Human Cytomegalovirus (HMCV) in Nicotiana tabacum Bright Yellow-2 (BY-2) suspension cells and of comparing its glycosylation profile with that of gB produced in Chinese hamster ovary (CHO) cells. gB was secreted in the BY-2 culture medium at a concentration of 20 mg/L and directly purified by ammonium sulfate precipitation and size exclusion chromatography. We then measured the relative abundance of N-glycans present on 15 (BY-2) and 17 (CHO) out of the 18 N-sites by multienzymatic proteolysis and mass spectrometry. The glycosylation profile differed at each N-site, some sites being occupied exclusively by oligomannosidic type N-glycans and others by complex N-glycans processed in some cases with additional Lewis A structures (BY-2) or with beta-1,4-galactose and sialic acid (CHO). The profiles were strikingly comparable between BY-2- and CHO-produced gB. These results suggest a similar gB conformation when glycoproteins are expressed in plant cells as site accessibility influences t...Continue Reading

References

Jul 2, 2003·Genome Génome / Conseil National De Recherches Canada·Eilleen S TackaberryAnil Dudani
Jan 9, 2007·Plant Biotechnology Journal·David LienardVéronique Gomord
Feb 12, 2008·Rapid Communications in Mass Spectrometry : RCM·Pilsoo KangMilos V Novotny
Apr 17, 2008·Molecular Biotechnology·Eilleen S TackaberryAnil K Dudani
Aug 3, 2010·Expert Review of Vaccines·Dirk Bosch, Arjen Schots
Jun 24, 2015·Plant Biotechnology Journal·Yoram TekoahYoseph Shaaltiel
Sep 15, 2015·Nature Communications·Sumana ChandramouliAndrea Carfi
Oct 21, 2015·PLoS Pathogens·Heidi G Burke, Ekaterina E Heldwein
Feb 13, 2016·Frontiers in Plant Science·Sébastien MercxMarc Boutry
Feb 26, 2016·Glycobiology·Richard Strasser
Mar 26, 2016·Frontiers in Plant Science·Rita B SantosTanja Holland
Apr 30, 2016·The Journal of Biological Chemistry·Ieva BagdonaiteHans H Wandall
May 11, 2016·Expert Review of Vaccines·Karen A MartinsJens H Kuhn
Apr 13, 2017·Journal of Proteomics·Laura Montero-MoralesHerta Steinkellner
May 19, 2017·Journal of Proteome Research·Kathrin GöritzerRichard Strasser
May 19, 2017·Nature Protocols·Shuang YangHui Zhang
Mar 27, 2018·Glycobiology·Ieva Bagdonaite, Hans H Wandall
Jun 8, 2018·Proceedings of the National Academy of Sciences of the United States of America·Mark R Schleiss
Jun 12, 2018·Plant Biotechnology Journal·Emmanuel MargolinAnn E Meyers
May 3, 2019·Journal of Proteome Research·Denis MorsaGabriel Mazzucchelli

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
glycosylation
ELISA
size exclusion chromatography
Protein Assay
gel filtration
reverse-phase chromatography

Software Mentioned

FlexAnalysis
Genewiz
Skyline
GlycoMod
MacCoss
Mascot engine

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.